Elosulfase alfa (2, reassessment) (Vimizim®) – Mucopolysaccharidosis (type IVA)

1. Characteristics

Start date 15.09.2017
Resolution 16.03.2018
INN Elosulfase alfa
Brand name Vimizim®
Company BioMarin Deutschland GmbH
G-BA procedure ID 2017-09-15-D-320
ATC code A16AB12
ICD-10 codes E76.2Other mucopolysaccharidoses
DDD 20 mg P
Therapeutic area Metabolic diseases ORPHAN
Reason for procedure Reassessment due to manufacturer request (§14)
Original resolution: Elosulfase alfa (20.11.2014)

Indication (German)

Vimizim is indicated for the treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages.

Subgroup Indication Comparator
Patienten aller Altersklassen mit Mucopolysaccharidose vom Typ IVA (Morquio A Syndrom, MPS IVA) – (Orphan drug)

9. Associated procedures

Resolution INN Brand name Indication Additional benefit
Elosulfase alfa Vimizim® Mucopolysaccharidosis (type IVA)
Elosulfase alfa (2, reassessment) Vimizim® Mucopolysaccharidosis (type IVA)

<< List of all resolutions